Introduction
The consumption of moderate amounts of cacao-based products (i.e. cocoa and dark chocolate) has been associated with a reduced risk for cardiovascular diseases (CVD) (1) (2) (3) (4) (5) .
Evidence suggests that the beneficial effects of cacao-based products may be mediated by improving endothelial function primarily, through an increase in the production of nitric oxide (NO) (3) . Cacao composition is complex and includes flavonoids present as monomers and polymers mainly of (−)-epicatechin ((−)-EPI) and (+)-catechin. The oral ingestion of pure (−)-EPI stimulates the production of NO by the vasculature (6, 7) , mimics the effects of cocoa consumption (7) and suggests (−)-EPI (a flavan-3-ol) as the molecule responsible of the aforementioned effects on the cardiovascular system. Using endothelial cells in culture, we have reported on the ability of (−)-EPI to stimulate NO production mediated by endothelial nitric oxide synthase (eNOS) stimulation through the activation of the PI3K/AKT and calcium (Ca 2+ ) (e.g. activation of Calmodulin and Ca 2+ /Calmodulindependent kinase II [CaMKII]) pathways (8) . These pathways are known to be linked with the activation of plasma membrane receptors that either posses intrinsic tyrosine kinase activity or couple to heterotrimeric G-proteins (9, 10) . By using a cell-surface impermeable (−)-EPI-dextran conjugate, we provided further evidence suggesting that (−)-EPI activates eNOS through a cell-surface receptor (11) . However, the exact nature of such entity(ies) has not been elucidated.
Flavonoids that are structurally similar to estrogen (e.g. the isoflavone genistein) are known to bind to the classical estrogen receptors (ERs) α and β leading to stimulation of the transcriptional activity of both receptors in the low nanomolar range (12, 13) . While (−)-EPI is structurally similar to estrogen, it does not appear to trigger transcriptional activity indicating that it does not interact with α or β ERs (14) .
The G protein-coupled estrogen receptor (GPER, once known as an orphan receptor) is a membrane-bound receptor that can couple to either Gα s or Gα i/o proteins, and binds 17βestradiol (15) as well as the high-affinity highly selective synthetic agonist G1 (16) . Activation of GPER leads to c-SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) via Gβγ and consequently, stimulation of ERK 1/2 (17) and PI3K/AKT/eNOS signaling pathways (18, 19) . Studies ascribe in part, the beneficial cardiovascular effects of estrogen to the stimulation of GPER (20) . Interestingly, recent evidence indicates that flavonoids such as s-equol can activate GPER linked signaling pathways (19) .
Given the similarities between GPER intracellular signaling linked pathways activation and those activated by (−)-EPI, we wished to test the hypothesis that GPER may act as a cellsurface receptor that can partly mediate the effects of (−)-EPI.
Materials and Methods

Chemicals and Reagents
Fetal bovine serum (FBS), charcoal stripped FBS, antibiotic-antimitotic solution, ActinGreen Alexa Fluor-488, Lipofectamine RNAiMAX, Opti-MEM 1 reduced serum media, and Dulbecco's Modified Eagle's Media (DMEM) with and without phenol red were from Life Technologies (Carlsbad, CA, USA). Bovine serum albumin (BSA) was from Tissue Culture Biologicals (Long Beach, CA, USA). Hank's Balanced Salt Solution (HBSS) phenol red free was from Mediatech Cellgro, Inc. (Herndon, VA, USA). MISSION® siRNA universal negative control #1, GPER specific siRNA, (−)-EPI, PP2, Tyrphostin AG 1498, pertussis toxin (PT), protease, and phosphatase inhibitor cocktails, Isobutylmethylxanthine (IBMX), and dimethyl sulfoxide (DMSO) were obtained from Sigma Aldrich (St. Louis, MO, USA). Primary antibodies, anti-phospho (p)-CaMKII (Thr 286 ), anti-pERK 1/2 (Thr 202 /Tyr 204 ), anti-CaMKII, anti-ERK 1/2, anti-GAPDH, and anti-rabbit and -mouse horseradish peroxidase (HRP)-conjugated secondary antibodies were from Cell Signaling (Danvers ,MA, USA). Anti-GPER was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary donkey anti-rabbit IgG conjugated to Alexa Fluor 594 was from Abcam (Cambridge, MA, USA). Lab-Tek II chamber slides and methanol-free formaldehyde (16 % in solution) were from Thermo Scientific (Waltham, MA, USA). VECTASHIELD mounting medium with DAPI was from Vector Laboratories Inc. (Burlingame, CA, USA). Immobilon-P Membrane, PVDF transfer membrane was from EMD Millipore (Bedford, MA, USA). Enhanced chemiluminescence (ECL) Plus Western Blot detection kit was from Amersham Biosciences (Piscataway, NJ, USA). G15 and G1 were from Cayman Chemical (Ann Harbor, MI, USA). cAMP ELISA kit was purchased from Enzo Life Sciences (Farmingdale, NY, USA).
Molecular modeling and molecular dynamic (MD) simulations
We used as a target the tridimensional (3-D) model of GPER previously developed, refined by molecular dynamics (MD) simulations and validated by docking studies (21) . This 3-D model of GPER was built using the GPCR I-Tasser web site (22) (a specialized server for building 3-D models of GPCRs). The 3-D model was evaluated by both the ERRAT (http:// nihserver.mbi.ucla.edu/ERRAT/) and PROCHECK (https://www.ebi.ac.uk/thornton-srv/ software/PROCHECK/) servers. The NAMD 2.9 program was used to perform the GPER refinement by MD simulations. The 14 and 70 ns snapshots derived from MD were used for docking studies, as these snapshots appeared to evidenced key molecular recognitions of G1 (agonist) and G15 (antagonist) in the binding site of GPER (21).
Molecular Docking studies
Docking studies were performed as previously described (21) , with slight modifications. Docking parameters employed here consisted on a grid box of 60 X 60 X 60 Å 3 centered at the Cα of F208, as this residue has been suggested by us and others (23) to be the protein active site centre, other parameters were kept the same. All analyzed ligands were drawn with ACD/CHEMSKETCH (http://www.acdlabs.com/resources/freeware/chemsketch/) and converted into 3-D structures (Z-matrix) with the Gauss view 5.0 program. Ligands were energetically and geometrically optimized at the AM1 semi-empirical level using the Gaussian 03 package. The prediction and description of GPER binding site with all ligands were carried out on AutoDock 4.2 software using the graphic interface AutoDock Tools 1.5.2.
Cell culture
Bovine Coronary Artery Endothelial Cells (BCAECs) were purchased from Cell Applications, Inc. (San Diego, CA, USA). BCAECs obtained from healthy bovine coronary arteries from 4 hearts were used in this study. A mouse skeletal muscle cell line (C2C12 myoblasts) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Both cell types were maintained at 37°C in an incubator with humidified atmosphere of 5 % CO 2 and cultured in DMEM supplemented with 10 % FBS and 1 % antibiotic and antimitotic solution.
Immunofluorescence
Cells were seeded onto glass slides pre-coated with 0.1 % gelatin, and incubated for 24 hr in growth medium. Thereafter, cells were washed with PBS and then fixed with a freshlyprepared cold 4 % formaldehyde solution in PBS for 10 min. Cells were permeabilized/ blocked with 3 % BSA, 0.3 M glycine and 0.1 % saponin in PBS for 1 h. Next, slides were incubated with anti-GPER (1:100, 3 % BSA in PBS) for 1 h at room temperature and thereafter washed 3x with PBS. To stain F-actin filaments, Alexa Fluor-488 phalloidin was used for 30 min and slides washed 3x with PBS. Next, Alexa Fluor 594-labeled anti-rabbit (1:400, PBS) was then used as secondary antibody for 1hr at room temperature and washed 3x with PBS. Finally, slides were vertically dried for 10 min and mounted on VECTASHIELD mounting medium with DAPI. 0.3 μm z-stacks were collected using an Olympus Confocal Microscope model FV1000-IX81 at 1024 x 1024 pixel resolution with a 60X objective lens.
siRNA Treatment
BCAEC were used at 40-50 % confluence in 6-well plates. Templates for siRNA were designed on the basis of the GPER bovine sequence and ordered from Sigma-Aldrich. Three designed siRNAs were pooled and their sequences are illustrated in Supplemental Table 2 . Negative control and specific GPER siRNAs (40 nM) were initially incubated with Lipofectamine RNAiMAX in Opti-MEM 1 media for 5 min to allow for the formation of siRNA-Lipofectamine complexes. As an additional control, Lipofectamine RNAiMAX in Opti-MEM 1 medium without any siRNA was used. Accordingly, the complexes and controls were added to cells that contained 2 ml of regular growth media per well. After 12 h of incubation, the transfection media was replaced by regular growth media and cells allowed to growth for 6 days. GPER knockdown efficacy was evaluated by Western Blotting.
Cell treatment
When cells reached 80 % confluence, growth media was replaced with phenol red-free DMEM supplemented with 1 % FBS (charcoal treated) and 1 % antibiotic and antimitotic solution and incubated for 12 h. Next, cells were maintained in phenol red-free HBSS supplemented with 0.4 mM L-arginine for 1 h. Inhibitors were used as follows (concentration, preincubation time): G15 (0.01-1 μM, 30 min), PP2 (1-5 μM, 30 min), Tyrphostin AG1498 (5-10 μM, 30 min) and PT (100 ng/mL, 12 hr). Inhibitors were present during ligand stimulation. (−)-EPI was used at 0.1 μM for 10 min based on previous studies (24) . As positive controls for select experiments forskolin and the GPER agonist, G1, were used at 1 μM and 0.1 μM for 10 min, respectively. (−)-EPI, G1, G15, AG1478 and forskolin were dissolved in DMSO (at a final concentration of 0.1 % v/v in the cells). PT was dissolved in water. DMSO at equal concentration was used as vehicle for control cells.
Total protein extraction
After cells were treated as above they were washed three times with cold HBSS (5 ml/well) and lysed in 100 μl of ice cold buffer (1% Triton X-100, 20 mmol/l Tris, 140 mmol/l NaCl, 2 mmol/l EDTA, and 0.1% SDS) with protease and phosphatase inhibitor cocktails supplemented with 1 mmol/l PMSF, 2 mmol/l Na3VO4, and 1 mmol/l NaF. Homogenates were sonicated for 10 min at 4°C, and centrifuged (12,000 g) for 10 min to remove cell debris. The total protein concentration was measured in the supernatant using the Bradford method.
Western Blot
Cells were treated and proteins extracted as described above. A total of 40 μg of protein was loaded onto a 4-15% SDS-PAGE, electrotransferred, incubated for 1 h or overnight in blocking solution (5% nonfat dry milk [NFM] or 5 % BSA in TBS [tris-buffered saline solution] plus 0.1% Tween 20 [TBS-T]), and followed by either 3 h incubation at room temperature or overnight incubation at 4°C with primary antibodies. Primary antibodies were typically diluted 1:1,000 or 1:2,000 in TBS-T plus 5% bovine serum albumin or 5 % NFM. Membranes were washed (3X for 5 min) in TBS-T and incubated 1 h at room temperature in the presence of HRP-conjugated secondary antibodies diluted 1:5,000 in blocking solution. Membranes were again washed 3X in TBS-T, and the immunoblots developed using an ECL detection kit. The band intensities were digitally quantified and phospho-proteins normalized against the total protein in study (i.e. relative phosphorylation was calculated).
cAMP assay
BCAEC were seeded on 24-well plates a density of 5x10 4 cells/well until they reached 80% confluence and prepared as noted above for agonist and antagonist stimulation. HBSS medium was supplemented with 100 μM of the phosphodiesterase inhibitor, IBMX for 15 min. After cells were stimulated, the media was aspirated by vacuum and cAMP was extracted twice with 0.5 mL ice-cold ethanol for 5 min at room temperature. The collected solvent was evaporated using a SpeedVac concentrator and the dry residue was resuspended in 0.2 mL of assay buffer. The amount of cAMP in the supernatants (using 0.1 mL and done in duplicate) was assayed using an ELISA kit according to the manufacturer's instructions. Cell density was assessed using the methylene blue method (25) , and results expressed as pmol/10 6 cells.
Animals
The aortas of male Wistar rats (250 to 300 g) were employed for ex vivo evaluations of the vascular effects of (−)-EPI. Rats were maintained at room temperature (18-25 °C) and on a 12 h light/dark cycle, with food and water provided ad libitum. Animals were handled in accordance with Mexican federal regulations for animal experimentation and care (NOM-062-ZOO-1999, Ministry of Agriculture, Mexico City, Mexico) and the good practices of the Comité Interno para el Cuidado y Uso de los Animales de Laboratorio (CICUAL) in regard to research with experimental animals.
Vascular reactivity
Under anesthesia (pentobarbital 60 mg/kg) animals were decapitated and the thoracic aorta from the diaphragm to the aortic arch was isolated. As previously done by us (26) , aortas were immediately submerged in cold Krebs solution to remove all adjacent connective tissue, then cut into ring segments (4-5 cm long), which were then mounted on two stainless steel hooks within an isolated organ chamber. One of the hooks was fixed to the bottom of the chamber and the other to a transductor linked to a Biopac System apparatus for registering changes in tension (force). The isolated organ chamber contained 10 ml of Krebs bicarbonate solution with the following composition in (mM): NaCl 11; KCl 4.7; KH 2 PO 2 1.2; MgSO 4 7; H 2 O 1.2; CaCl 2 , 2H 2 0 2.5; NaHCO 3 25; dextrose 11.7 and calcium disodium EDTA 0.026. The chamber was maintained at a constant temperature of 37°C, pH of 7.4 and a continuous bubbling with a mixture of 95% O 2 and 5% CO 2 .
Compounds were dissolved in DMSO and sequentially diluted in buffer to a final DMSO concentration of less than 0.1%. Standard concentration-response curves were constructed to analyze vascular reactivity to (−)-EPI and G1 [1x10 −11 to 1x10 −5 M] on pre-contracted rings (phenylephrine [1x10 −6 M]) and compared to the effects induced by the GPER agonist G1. A second series of experiments were performed in the presence of the GPER antagonist G15 [1 μM]. Arteries were incubated during 30 minutes with the antagonist before concentration-response curves to (−)-EPI effects were performed. To avoid the oxidation of (−)-EPI bubbling with 95% O 2 was suspended just before its addition to the bath chamber, this maneuver did not affect the contraction of phenylephrine nor the dilation to acetylcholine (data not shown). No effect was observed with DMSO at the final concentration used with the compounds.
Statistical analysis
Data are presented as mean ± SEM derived from at least three independent experiments performed each in triplicate. Statistical analysis of data was performed using one-way ANOVA followed by the Tukey post hoc test or Student's t-test for unpaired data, as appropriate. All data was graphed and analyzed using Prism 3.0 (GraphPad Software, San Diego, CA). Data was considered significant when p values obtained were <0.05.
Results
Molecular modeling, MD simulations and molecular docking
In order to evaluate the plausible binding mode between (−)-EPI ( Fig. 1A) and GPER, we employed in silico studies. As previously reported by us, we have combined MD simulations and docking studies to explore the potential ligand binding sites of GPER (21) . We have focused on 14 and 70 ns conformers retrieved from MD simulations for the subsequent docking analysis as these conformers were capable to accept G1 and G15 in the same binding pose under a blind docking procedure (21) . The docking results on 14 ns GPER conformer ( Fig. 2A-D) show that G1 and (−)-EPI posses a similar binding pose and both reached the aminoacid residues L137, Q138, M141, Y142, F208, Q215, E218, V219 (Supplemental Table 1 ). Conversely, in this study (using a focused docking) G15 reaches and adjacent site ( Fig. 2C and 2D ), contrary to our previous blind docking study (21) .
Results suggest that the chemical nature of the interactions between (−)-EPI and 14 ns GPER conformer are mainly π-π interactions with the aromatic residues F208 and Y142 and an additional hydrogen bond with the side chain of E218 ( Fig. 2A and supplemental Fig.  S1 , which importantly contributes to the binding free energy value (ΔG = −7.9 kcal/mol) (Supplemental Table 1 ). Using the 70 ns GPER conformer, we show that G1 ( Fig. 2B ) and G15 (Fig. 2C ) posses the same binding pose and reach the same aminoacid residues (Fig. 2D) as previously described under blind docking procedure (21) . (−)-EPI reaches the same binding site of G1 and G15 ( Fig. 2D and 2H) although; it makes interactions with more aminoacid residues (Supplemental Table 1 ). Specifically, (−)-EPI makes π-π interactions with W272 and F208, as well as hydrophobic interactions with the side chains of E218, C207 and Q215, and an additional hydrogen bond with E275 ( Fig. 2E ). G1 makes π-π interactions with F208 and hydrophobic interactions with the side chains of M141, Q138, M133 (Fig. 2F ). G15 has the same structural binding pose and the same non-bond interaction than G1. Remarkably, although G15 lacks an acetyl group compared to G1, its binding energy is more favorable than G1 (Fig. 2G) . The specific distances between the interacting ligand and residues atoms are shown in Supplemental Table 3 .
GPER expression
Receptor expression at the protein level was evaluated by immunoblotting using a polyclonal antibody against the N-terminal domain of GPER. The data shows the presence of a band at ~38 KDa in BCAEC (Fig. 3A, lane 1) that corresponds to the predicted molecular weight of GPER. Moreover, as positive and negative controls we used lysates from C2C12 and HEK293 cells, respectively. For C2C12 (Fig. 3A, lane 3) a band at ~ 38 KDa was also detected. In HEK293, there was a relative very low immunodetection compared to the other cell types (Fig. 3A, lane 2) as reported by others (27) .
GPER localization
In order to determine the subcellular localization of GPER we performed a z-stack analysis using confocal immunofluorescence microscopy. GPER immunostaining of fixed and permeabilized BCAEC denoted a web-like appearance suggesting receptor localization on a cytoskeletal structure (Fig. 4A ). To further address this issue, we used phalloidin conjugated to Alexa Fluor-488 to stain F-actin ( Fig. 4B ). As shown in Fig. 4C there appears to be extensive co-localization between GPER and F-actin filaments. Images also show localization of GPER at the cell-surface (Fig. 4D ).
(−)-EPI-induced GPER-mediated activation of ERK 1/2 and CaMKII
We evaluated the activation of ERK 1/2 and CaMKII kinases that are associated to GPER stimulation (17, 28, 29) . (−)-EPI effects on ERK 1/2 and CaMKII activation were assessed in the presence or absence of the selective GPER antagonist, G15 (30) . Cells were stimulated with (−)-EPI 0.1 μM for 10 min, which evokes peak effect on endothelial cell signaling as previously reported by us (24) . (−)-EPI treatment led to the activation of ERK 1/2 and CaMKII as denoted by their phosphorylation (Fig. 5A ). G15 at 1 μM completely blocked the effects of (−)-EPI on ERK 1/2 and CaMKII activation as shown in Fig. 5A and Figs. 6A and 6B.
EGFR expression
To further elucidate the mechanism associated to GPER activation by (−)-EPI, we examined the presence of EGFR, which is known to be trans-activated by GPER, and can lead to the activation of ERK 1/2 (17) . As illustrated in Fig 5. B, all immunoblots demonstrated the presence of a band at ~175 KDa in BCAEC (lane 1), HEK293 (lane 2) and C2C12 (lane 3) that corresponds to the molecular weight of EGFR.
(−)-EPI-induced activation of ERK 1/2 and CaMKII is EGFR-and c-SRC-dependent
Reports indicate that GPER can trans-activate EGFR through the participation of c-SRC (17) . To examine this issue in our model, we first blocked EGFR activity using its selective antagonist AG1478 (5-10 μM) (31) . AG1478 at 5 μM completely abrogated the effects of (−)-EPI on ERK 1/2 and CaMKII, as noted in Fig. 5C and Figs. 6C and 6D. We also inhibited c-SRC by using a selective antagonist PP2 (1-5 μM) (32) . PP2 at 3 μM completely blocked the effects of (−)-EPI on the kinases as shown in Fig. 5D and Figs. 6A and Fig. 6B. 
G1-induced activation of ERK 1/2 is GPER/c-SRC/EGFR dependent
We employed the GPER agonist, G1, as a positive control to compare its effects with those of (−)-EPI. We used the lowest concentration of the antagonists that completely blocked the effects of (−)-EPI on ERK 1/2. At equimolar concentrations (0.1 μM) G1 activated ERK 1/2 with no significant differences in the magnitude of the effect compared with (−)-EPI. As expected, G15 blocked G1 activation of ERK 1/2 (Fig.7A ). AG1478 (Fig.7B ) and PP2 (Fig.  7C ) also blocked G1 activation of ERK 1/2.
ERK 1/2 activation by (−)-EPI is not PT-sensitive
GPCRs can couple to PT-sensitive G i/o -proteins leading to the activation of ERK 1/2 (33) . Apparently, GPER-mediated activation of ERK 1/2 can be dependent on G i/o -proteins sensitive to PT (17, 34) . By the use of PT we therefore examined the role that G i/o may have on EPI-and G1-mediated ERK 1/2 activation. As shown in Fig. 8A and Fig. 8B PT did not block ERK 1/2 activation by either (−)-EPI or G1, respectively.
Effects of (−)-EPI and G1 on cAMP levels
GPER can also couple to Gα s , which in turn can lead to increased cAMP levels (35) (36) (37) . We thus, addressed the capacity of (−)-EPI and G1 to increase cAMP levels. As a positive control, we use forskolin, which increases cAMP levels through a mechanism that involves direct binding to adenylyl cyclase (38) . As expected, forskolin doubled cAMP level compared to control (Fig. 8C ), while neither (−)-EPI nor G1 increased it (Fig. 8C ).
Effects of siRNA on (−)-EPI-and G1-induced ERK 1/2 activation
In order to provide additional support for our findings, we employed three pooled siRNAs targeting GPER to reduce its expression and evaluate the effects of (−)-EPI and G1 on ERK 1/2 activation. Our results show decreased GPER protein levels (67 %vs. transfection reagent) with the use of siRNA against GPER, no effect was observed with the use of nontargeting siRNA (Fig. 9A) . Moreover, the effects of (−)-EPI and G1 on ERK 1/2 were attenuated by the use of siRNA targeting GPER (Fig.9B ).
Effects of (−)-EPI and G1 on pre-contracted rat arteries
As a relevant physiological model to evaluate GPER activation, we employed phenylephrine pre-contracted arteries to study the vascular effects of GPER ligands as used by others (39) (40) (41) . Using isolated aortic rings we evidence concentration-dependent vasodilatory effects of (−)-EPI that are comparable to those generated by the agonist G1 (Fig. 10A) . Pretreatment with the GPER antagonist G15 [1μM] significantly attenuated the (−)-EPI response (Fig.  10B) . Similarly, the effect of (−)-EPI on the activation of eNOS ( Fig. 10C ) and NO production ( Fig. 10D ) in BCAEC was also attenuated with G15 [1μM].
Discussion
In this study, we evaluated by in silico analysis, the binding mode of (−)-EPI on GPER. The interaction of (−)-EPI on GPER yields a favorable thermodynamic interaction similar to that described for the GPER ligands, G1 and G15. Moreover, (−)-EPI reaches the same binding site and shares similar molecular recognition properties to those observed for G1 at either 14 and 70 ns GPER conformers under focused docking. GPER is present in endothelial cells as it was localized at the cell-surface and also along cytoskeletal structures (F-actin filaments). (−)-EPI-mediated ERK 1/2 and CaMKII activation was reliant on GPER/c-SRC/EGFR and independent of Gα i/o and Gα s . Moreover, (−)-EPI mediates vasodilation and eNOS activation through GPER. Altogether, our results indicate that GPER is a receptor, which has the capacity to mediate (−)-EPI effects on endothelial cells.
Over the past years, we have reported on the capacity of (−)-EPI to activate upstream intracellular signaling pathways that are known to be associated to the activation of GPCRs or tyrosine kinase receptors (8, 11) . However, the identification of such entities remained lacking. Gathering of evidence for receptor activation by flavonoids can serve to dispel the notion that this class of natural compounds simply exerts their effects by acting as antioxidants. In this regard, there is precedent for the involvement of other GPCRs (such as GPR120) in mediating the beneficial effects of natural molecules such as omega-3 fatty acids (42) .
Given the observation that the intracellular signaling pathways linked to GPER are very similar to those activated by (−)-EPI and its structural similarity to s-equol ( Fig. 1B) we performed a series of experiments evaluating the participation of this receptor in mediating its effects. In silico studies (i.e. docking and MD simulations) have greatly aided in drug discovery by predicting the binding of molecules with existing or recently discovered orphan receptors (43) . For example, the virtual and biomolecular screening of putative GPER ligands led to the identification of the first non-steroidal, high-affinity and highly selective GPER ligand, G1 (16) and recent docking studies have evidenced the favorable binding mode of synthetic compounds to GPER (23, (44) (45) (46) , which clearly indicates that in silico docking simulations greatly contribute to the discovery of GPER ligands (47) . Therefore, as an initial strategy, we employed docking studies using a GPER 3D model (previously validated by our group) that was further refined by MD simulations (21) . In this study, we used two conformers retrieved from MD simulations and validated by docking. It is worth noting that we incorporated protein motion into our 3D model of GPER by using MD simulations, which provides a more physiological receptor environment as described elsewhere (48) . The use of MD simulations in conjunction with docking studies is proposed to predict in a more reliable manner protein-ligand complexes in comparison to rigid docking (49, 50) . Based on our previous study (21) , we focused on two GPER conformers derived from MD simulations (14 and 70 ns) that suggest a possible state of activation/ inactivation switch of the receptor by the accommodation pattern of G1 and G15 into the binding site (21) . Moreover, as mentioned above we have focused on the residue F208, which has been suggested as the GPER protein active site centre (21, 23, 51) . Our virtual simulations suggest that the interaction between (−)-EPI and GPER is energetically favorable and similar to the GPER agonist G1. Interactions with the 14 ns conformer are mainly through aromatic π-π interaction with (−)-EPI sharing the same GPER binding site with G1, whereas G15 is located outside the mentioned binding site. The interaction between (−)-EPI and G1 with the receptor only differed by two amino acid residues (F223, W272 for G1 and E275, N276 for (−)-EPI, see Supplemental Table 1 ), while G15 interacted altogether with different amino acids residues. In contrast, using the retrieved 70 ns conformer from MD we denote that the binding mode of all ligands is very similar. However, G15 increased its binding affinity (ΔG becomes more negative) towards the receptor.
The first report of GPER as an orphan receptor was recorded from human umbilical vein endothelial cells (HUVEC) subjected to fluid shear stress (52) . However, the presence of this receptor has been noted throughout other cellular components of the cardiovascular system such as smooth muscle cells (20) . Interestingly, the majority of studies evaluating the effects of GPER on endothelial cells have focused on the use of HUVECs (53) (54) (55) (56) . Here, we evidenced for the first time the presence of GPER in coronary artery endothelial cells.
The subcellular localization of GPER has been amply debated. Studies report its presence on the Golgi apparatus (18), endoplasmic reticulum (18, 57) , cell-surface (27, 58, 59) and nuclei (54, 60, 61) . To address this issue in BCAECs, we used confocal imaging z-stack analysis. Using double staining, we evidence the presence of GPER at the cell-surface and in co-localization with cytoskeletal structures, F-actin filaments. The localization of GPER on cytoskeletal-like cellular structures has been previously demonstrated, and appears associated to receptor trafficking (58) . However, the biological significance of GPER presence on F-actin filaments is beyond the scope of this study. Interestingly, using a cellsurface impermeable (−)-EPI dextran conjugate, we noted that its effect on intracellular signaling was comparable to that generated by (−)-EPI (11) . Given these results, it appears that a cell-surface localization of GPER is likely responsible for (−)-EPI-mediated activation of intracellular pathways in endothelial cells.
Our results indicate that (−)-EPI increases the activity of ERK 1/2 and CaMKII through GPER activation, which can be effectively blocked by G15. Similarly, the use of siRNA confirms the role that GPER has on mediating ERK1/2 activation by (−)-EPI. Critical to the activation of those kinases, is the crosstalk with EGFR as evidenced by the blockade of effects elicited by the EGFR blocker AG1478. These results are in agreement with those of Filardo et al. who suggests that E 2 -mediated ERK 1/2 activation is dependent upon transactivation of the EGFR via GPER-mediated increase in c-SRC kinase activity through a mechanism that involves the Gβγ-subunit protein (17) . We also examined the role that c- 
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Author Manuscript SRC has on (−)-EPI activation of ERK 1/2 by using the selective c-SRC antagonist PP2, which fully blocked its effects. By its mimicry of G1 effects, we also provide further evidence on the reliance of (−)-EPI actions on the GPER/c-SRC/EGFR system.
Depending on the cell type under investigation, the subtype of Gα protein associated to GPER has been ascribed so far, to the Gα i/o or Gα s subgroups (17) . Our results suggest that the Gα protein coupled to GPER in BCAEC is neither Gα s nor Gα i/o due to the inability of PT to block (−)-EPI or G1 activation of ERK 1/2 and lack of changes in cAMP levels seen after ligand stimulation of endothelial cells. Interestingly, the activation of GPER has been linked to a rapid and transient intracellular Ca 2+ increase, which is still poorly understood as to whether its directly mediated by Gα q or EGFR (62) . Thus, we do not rule the plausible participation of a Gα q in GPER mediated activation of intracellular signaling in BCAEC.
In the vasculature, GPER activation by G1 has been associated to vasodilation in part by activation of eNOS and NO production (35, 41) . We therefore, employed phenylephrine precontracted aortic rings as an ex vivo model to evaluate the role that GPER has on mediating (−)-EPI vasodilatory effects. Our results indicate that (−)-EPI causes vasodilation in a concentration-dependent manner that is not different from that observed with G1 and is mediated by GPER activation. Moreover, to assess the role that eNOS has on mediating the (−)-EPI vasodilatory effects through GPER; we evaluated its phosphorylation (Ser1179) and NO production in BCAEC. Our data suggest that (−)-EPI activates eNOS and stimulates NO production through GPER activation, as evidenced by the partial blockade elicited by G15.
Overall, using in silico and in vitro studies we evidenced on the capacity of (−)-EPI to activate intracellular pathways similar to those observed by the GPER agonist, G1, which are mediated by GPER cross-talk with the EGFR, via the kinase c-SRC. These results have important implications as they provide rigorous evidence as to a plausible mechanism of action of (−)-EPI in triggering effects in normal endothelial cells, which may partly account for the protective actions of flavanols on the cardiovascular system. Effects of the GPER agonist G1, on ERK 1/2 activation in the presence of G15, AG1478 and PP2 blockers. BCAEC were incubated with 0.1 μM G1 for 10 min without or with (30 min previous and during ligand stimulation) (A) 1 μM G15, (B) 5 μM AG1478 and (C) 3 μM PP2. Top panels show representative blots of phosphorylated ERK 1/2 and total protein levels. Bottom panels quantify the effects of G1 with or without the chemical blocker. Control was arbitrarily set to 1 and kinase activation is expressed as relative to phosphorylation. Values are means ± SEM. * P<0.05, ** P<0.01, *** P<0.001. Proposed role for GPER and EGFR in the mediation of (−)-epicatechin ((−)-EPI) effects on Bovine Coronary Artery Endothelial cells (BACEC) leading to the activation of ERK 1/2 and CaMKII. 
